search
Back to results

Comparison of Low, Moderate and High Carbohydrate Diet on Insulin Requirements and Metabolic Control in Type 1 Diabetes (DANCE)

Primary Purpose

Type1diabetes

Status
Active
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
traditional diabetes diet
moderately low carbohydrate diet
strictly low carbohydrate diet
Sponsored by
Anneli Björklund
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type1diabetes focused on measuring type 1 diabetes, low carbohydrate diet, randomized trial, adults, insulin, metabolic control

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • To have had type 1 diabetes for at least 1 year
  • Age >=20 years old

Exclusion Criteria:

  • Cardiovascular disease NYHA class IIIB or more
  • Kidney disease > stadium 3
  • Liver disease, alanine aminotransferase (ALAT) ≥ 2 µkat/L,
  • BMI < 18.5 kg/m^2
  • c-peptide ≥ 0.3 nmol/l
  • Pregnant/breastfeeding women, women that plan to get pregnant during study period
  • Other circumstances, which, according to the examiner, make it difficult for an individual to participate.

Sites / Locations

  • Center for Diabetes, Academic Specialistcenter

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

traditional diabetes diet

moderately low carbohydrate diet

strictly low carbohydrate diet

Arm Description

Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake

Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake

Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake

Outcomes

Primary Outcome Measures

Change in insulin use
measured in international units (IU) and percentage.

Secondary Outcome Measures

Change in HbA1c
mmol/mol
Change in concentration of total cholesterol
mmol/L
Change in concentration of triglycerides
mmol/L
Change in concentration of HDL-cholesterol
mmol/L
Change in concentration of LDL-cholesterol
mmol/L
Ratio of LDL/HDL
absolute number
Concentration of glucagon
pmol/L
Change in markers of glycemic variability (TIR, TAR, TBR, mean sensor glucose with SD, CV)
mmol/L
Change in weight
kg
Change in BMI
kg/m^2
Change in abdominal circumference
cm
Change in concentration of p-creatinine
micromol/L
Change in estimated Glomerular Filtration Rate (eGFR)
mL/min/1,73 m2
Change in microalbuminuria
morning U-Alb/Crea (mg/mmol)
Concentration of Insulin-like Growth Factor 1 (IGF-I)
microg/L
Concentration of Insulin-like Growth Factor - binding protein 1 (IGFBP-1)
microg/L
Concentration of leptin
microg/L
Concentration of adiponectin
mg/L
Concentration of interleukin 6 (IL-6)
ng/L
Concentration of high sensitivity c-Reactive Protein (Hs-CRP)
mg/L
Measurement of lipopolysaccharides (LPS) activity using the Limulus Amebocyte Lysate (LAL) assay
measured in endotoxin units (EU)/ml
Concentration of glutaredoxin 1 (GRX-1)
Concentration of Oxidized LDL
Total Antioxidant Capacity (TAC)
Concentration of reactive oxygen species (ROS)
Plasma metabolites assessed by untargeted liquid chromatography - mass spectrometry (LC-MS) metabolomics
Score from the Short Form 36 (SF-36) questionnaire
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Score from the Well-being Questionnaire-12 (WBQ-12)
This questionnaire is designed to measure general well-being, including negative well-being, energy and positive well-being. The negative well-being scale score (range 0-12) is reversed and then summed with the Energy score (range 0-12) and Positive score (range 0-12) to produce a general well-being score (range 0-36). The higher the score the greater the sense of general well-being.
Score from the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
The DTSQ has been developed to assess patient satisfaction with diabetes treatment. The questionnaire is composed of two different factors. The first factor assesses treatment satisfaction and consists of six questions and the second factor consists of two questions, which assess the burden from hyper- and hypoglycemia. Treatment satisfaction is assessed as the sum of the scores of the six questions on the first factor (total score 36), with a higher score indicating higher treatment satisfaction.
Time taken to complete the Trail making test A+B
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The time taken to complete the test is used as the primary performance metric, measured in seconds and or minutes.

Full Information

First Posted
November 26, 2018
Last Updated
September 27, 2023
Sponsor
Anneli Björklund
Collaborators
Uppsala University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03761186
Brief Title
Comparison of Low, Moderate and High Carbohydrate Diet on Insulin Requirements and Metabolic Control in Type 1 Diabetes
Acronym
DANCE
Official Title
DANCE (Diabetes ANd CarbohydratEs). Does the Amount of Dietary Carbohydrates Affect Insulin Requirements and Metabolic Control in Type 1 Diabetes? Comparative Study of Traditional Diabetes, Moderately Low and Strictly Low Carbohydrate Diet
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 12, 2018 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Anneli Björklund
Collaborators
Uppsala University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The scientific basis for dietary recommendations in type 1 diabetes is almost lacking, with the current recommendations being based on type 2 diabetes studies. Therefore the overall purpose of this study is to improve the current evidence for dietary recommendations to people with type 1 diabetes. Study aim: To compare how a strictly low carbohydrate diet, a moderately low carbohydrate diet and a traditional diabetes diet (with higher amounts of carbohydrates) affect insulin requirements and metabolic control in individuals with type 1 diabetes. Carbohydrate intake is 50-60% of the total energy intake in the traditional diabetes diet, 30-40% in the moderately low carbohydrate diet and 15-20% in the strictly low carbohydrate diet with a minimum of 50 g carbohydrates/day. A diet with less than 50 g carbohydrates/day is usually called very low carbohydrate diet or ketogenic and will not be tested in this study. Those who wish to participate and meet the inclusion criteria (and none of the exclusion criteria) will be randomized to one of the three diets. The duration of the intervention is 6 months after which the participants will be able to choose their own diet for another 6 months. The main study visits are at baseline (screening and study start), 3, 6, 9, and 12 months. Shorter visits will be at 3 and 6 weeks. The participants will meet with a study nurse, dietitian and doctor. They will attend two carbohydrate counting courses before the start of the intervention in order to be able to match their insulin to the amount carbohydrates they eat. Participants will receive written materials about their diets with menus and recipes for better adherence to the diet. The primary endpoint is the change in insulin requirements within and between groups (for secondary endpoints please see relevant section). For assessing the different endpoints the participants will provide blood, urine and feces samples for lab analyses as well as register their insulin use, blood glucose, diet, physical activity and any blood ketones or hypoglycemia electronically or in written forms. Continuous/flash glucose monitoring (CGM/FGM) will be also used. Dietary assessment and adherence will be based on 3-4 day food diaries before every scheduled study visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1diabetes
Keywords
type 1 diabetes, low carbohydrate diet, randomized trial, adults, insulin, metabolic control

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Nurses that will take lab samples as well as laboratory personal that analyses the samples will be masked. Due to the nature of the study, it is not possible to mask the participants or the care providers/investigators.
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
traditional diabetes diet
Arm Type
Active Comparator
Arm Description
Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
Arm Title
moderately low carbohydrate diet
Arm Type
Experimental
Arm Description
Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
Arm Title
strictly low carbohydrate diet
Arm Type
Experimental
Arm Description
Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
Intervention Type
Behavioral
Intervention Name(s)
traditional diabetes diet
Intervention Description
Diet with carbohydrate content 50-60% of total energy intake
Intervention Type
Behavioral
Intervention Name(s)
moderately low carbohydrate diet
Intervention Description
Diet with carbohydrate content 30-40% of total energy intake
Intervention Type
Behavioral
Intervention Name(s)
strictly low carbohydrate diet
Intervention Description
Diet with carbohydrate content 15-20% of total energy intake
Primary Outcome Measure Information:
Title
Change in insulin use
Description
measured in international units (IU) and percentage.
Time Frame
screening, day 0, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Secondary Outcome Measure Information:
Title
Change in HbA1c
Description
mmol/mol
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Change in concentration of total cholesterol
Description
mmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in concentration of triglycerides
Description
mmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in concentration of HDL-cholesterol
Description
mmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in concentration of LDL-cholesterol
Description
mmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Ratio of LDL/HDL
Description
absolute number
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of glucagon
Description
pmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in markers of glycemic variability (TIR, TAR, TBR, mean sensor glucose with SD, CV)
Description
mmol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in weight
Description
kg
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Change in BMI
Description
kg/m^2
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Change in abdominal circumference
Description
cm
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Change in concentration of p-creatinine
Description
micromol/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in estimated Glomerular Filtration Rate (eGFR)
Description
mL/min/1,73 m2
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Change in microalbuminuria
Description
morning U-Alb/Crea (mg/mmol)
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of Insulin-like Growth Factor 1 (IGF-I)
Description
microg/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of Insulin-like Growth Factor - binding protein 1 (IGFBP-1)
Description
microg/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of leptin
Description
microg/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of adiponectin
Description
mg/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of interleukin 6 (IL-6)
Description
ng/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of high sensitivity c-Reactive Protein (Hs-CRP)
Description
mg/L
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Measurement of lipopolysaccharides (LPS) activity using the Limulus Amebocyte Lysate (LAL) assay
Description
measured in endotoxin units (EU)/ml
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of glutaredoxin 1 (GRX-1)
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of Oxidized LDL
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Total Antioxidant Capacity (TAC)
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Concentration of reactive oxygen species (ROS)
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Plasma metabolites assessed by untargeted liquid chromatography - mass spectrometry (LC-MS) metabolomics
Time Frame
screening, 3 months, 6 months, 9 months, 12 months
Title
Score from the Short Form 36 (SF-36) questionnaire
Description
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Score from the Well-being Questionnaire-12 (WBQ-12)
Description
This questionnaire is designed to measure general well-being, including negative well-being, energy and positive well-being. The negative well-being scale score (range 0-12) is reversed and then summed with the Energy score (range 0-12) and Positive score (range 0-12) to produce a general well-being score (range 0-36). The higher the score the greater the sense of general well-being.
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Score from the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Description
The DTSQ has been developed to assess patient satisfaction with diabetes treatment. The questionnaire is composed of two different factors. The first factor assesses treatment satisfaction and consists of six questions and the second factor consists of two questions, which assess the burden from hyper- and hypoglycemia. Treatment satisfaction is assessed as the sum of the scores of the six questions on the first factor (total score 36), with a higher score indicating higher treatment satisfaction.
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Time taken to complete the Trail making test A+B
Description
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The time taken to complete the test is used as the primary performance metric, measured in seconds and or minutes.
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Other Pre-specified Outcome Measures:
Title
Carbohydrate intake
Description
in grams/day
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Energy intake from carbohydrates
Description
% of total energy intake
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Daily energy intake of participants
Description
kcal/day
Time Frame
screening, 3 weeks, 6 weeks, 3 months, 6 months, 9 months, 12 months
Title
Frequency of intake of different foods measured by a Food frequency questionnaire (FFQ)
Description
The participants will fill in how frequent they consume 132 different food items. The available frequency responses are: 0/month, 1-3/month, 1-2/week, 3-4/week, 5-6/week, 1/day, 2/day, 3+/day.
Time Frame
screening, 6 months,12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: To have had type 1 diabetes for at least 1 year Age >=20 years old Exclusion Criteria: Cardiovascular disease NYHA class IIIB or more Kidney disease > stadium 3 Liver disease, alanine aminotransferase (ALAT) ≥ 2 µkat/L, BMI < 18.5 kg/m^2 c-peptide ≥ 0.3 nmol/l Pregnant/breastfeeding women, women that plan to get pregnant during study period Other circumstances, which, according to the examiner, make it difficult for an individual to participate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anneli Björklund, MD, PhD
Organizational Affiliation
Department of Endocrinology at Karolinska University Hospital and Academic Specialistcentrum
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Diabetes, Academic Specialistcenter
City
Stockholm
ZIP/Postal Code
11365
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Comparison of Low, Moderate and High Carbohydrate Diet on Insulin Requirements and Metabolic Control in Type 1 Diabetes

We'll reach out to this number within 24 hrs